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ABSTRACT: Urothelial carcinoma of the bladder represents the majority of malignant bladder tumors. Metastases to 
skeletal muscle from carcinoma of the bladder are extremely rare and are tend to be found in people with advanced-stage 
carcinoma. In this article we present a man with an unusual metastasis to the left sartorius muscle from an urothelial cell 
carcinoma, who was submitted in surgery and then in concomitant chemotherapy and external radiation therapy as 
palliative therapy. 
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INTRODUCTION 
 
Bladder cancer is a common urological cancer with 
significant morbidity and mortality. Approximately 
90% of all bladder cancers are urothelial (transitional 
cell) carcinomas and only 5% are squamous cell 
carcinomas.(1) Although the disease is locally 
controlled, many patients will ultimately develop 
distant metastases. Metastases to skeletal muscle from 
carcinoma of the bladder are extremely rare and are 
tend to be found in people with advanced-stage 
neoplasm.(2) Only a few reported cases have been 
published worldwide.(3) In this article we present an 
unusual metastasis to the left sartorius muscle from an 
urothelial cell carcinoma. 
 
CASE PRESENTATION 
 
A 56 year old man was referred to our hospital with 
reported severe muscular pain in the left thigh which 
presented the last month. He had a history of bladder 
carcinoma and for that reason he undergone a radical 
cystectomy with bilateral pelvic lymph node dissection 
one year ago. According to the histological report it was 
a high grade (Grade III) urothelial carcinoma, stage 
T3N0Mx with negative surgical margins. In the context 
of his regular follow-up, the patient underwent a pelvic 
CT, where there was found a bulge of the left sartorius 
muscle and impurity of its subcutaneous fat. The patient 
underwent an MRI which revealed a well circumscribed 
mass with dimensions 3x1, 7cm, with heterogeneous 
high magnetic signal in T1 sequences. The patient 
underwent surgery where the left sartorius muscle with 
dimensions 9x4x3.9cm was removed. Histology 
showed that this is a metastasis from the already known 
urothelial cancer with neoplastic cells which were 
strongly positive in the CK7 and negative in CK20, 
while the cellular proliferation index ki67 was about 
40%. The surgical margins were positive and for that 
reason the patient was submitted in concomitant 
chemotherapy and radiation therapy. He was submitted 
in 6 cycles of intravenous chemotherapy consisted of 
Gemsitabine and Cisplatin and was referred to the 
Radiotherapy Department for IFRT (Involved Field 
Radiation Therapy) with a total dose volume of 20 Gy 
in 4 sessions with a daily dose volume of 5 Gy. The 
therapy was performed in a linear accelerator with 
6MeV energy and 0.5cm margin from the bed of the 
tumor. The patient was followed up 1 month later with 
clinical examination and he reported a reduction of the 
pain  
 
DISCUSSION 
 
Urothelial (transitional cell) carcinoma of the bladder 
represents the majority of malignant bladder tumors. 
The most frequent sites of metastases are to lymph 
nodes, lung and bones. Haematogenous metastasis to 
skeletal muscles is uncommon and approximately 100 
cases have been reported worldwide. 
Skeletal muscles receive a great portion of the total 
cardiac output as it represents the half of the total body 
mass. However, hematogenous metastatic disease to the 
skeletal muscle is extremely rare and has a worse 
prognosis than a metastasis to any other organ.(4) There 
are various factors that can describe the resistance of 
skeletal muscle to metastatic disease, such as muscle 
motion, muscle pH which creates a hostile environment 
for the tumor growth, as well as the muscle’s ability to 
remove tumor- produced lactic acid that induces tumor 
neovascularity.(2, 5) Despite all these defensive factors, 
there have been reported metastases to skeletal muscles 
from malignancies of the pancreas, colon and lung.(2, 
6) Metastatic disease to skeletal muscles tends to be 
found in advanced- stage neoplasms and the most 
common sites of metastatic involvement are the largest 
muscles, such as psoas and gluteus. 
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In our case, the patient presented with muscular pain, 
which is compatible with some studies showing that 
most lesions are painful. 
The majorities of patients with metastasis in skeletal 
muscles develop widespread disease and die in a mean 
duration of 8 months. Effective palliation can be 
achieved with chemotherapy and local radiotherapy, 
according to the few existing data. These small series 
also indicate that skeletal muscle metastasis from 
transitional cell carcinoma has a poor prognosis.(4) 
In conclusion localized swellings in muscles, in patients 
with bladder carcinoma, that present with or without 
pain should be followed by CT scan so as to exclude the 
possibility of a distant metastasis. Median time to 
diagnosis of distant metastasis is 18 months. Clinicians 
should be aware of atypical presentation of skeletal 
muscle metastasis, so as to perform as soon as possible 
a lesion biopsy and start the shortest possible the 
proposed palliative treatment.
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Μετάσταση ουροθηλιακού καρκινώματος στον ραπτικό μυ 
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ΠΕΡΙΛΗΨΗ: Το ουροθηλιακό καρκίνωμα της ουροδόχου κύστης αντιπροσωπεύει την πλειοψηφία των κακοηθών όγκων 
της ουροδόχου κύστης. Οι μεταστάσεις σε σκελετικούς μύες από καρκίνωμα της ουροδόχου κύστης είναι εξαιρετικά 
σπάνιες και τείνουν να εμφανίζονται σε άτομα με προχωρημένη νόσο. Σε αυτό το άρθρο παρουσιάζουμε μία περίπτωση 
ασυνήθιστης μετάστασης στον αριστερό ραπτικό μυ από ένα ουροθηλιακό καρκίνωμα, η οποία αντιμετωπίστηκε με 
χειρουργική επέμβαση και στη συνέχεια με ταυτόχρονη χημειοθεραπεία και ακτινοθεραπεία ως παρηγορητική θεραπεία. 
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